Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology, Genentech, Lilly, Merck, Inc., and Novartis Oncology.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
9th Annual New York Lung Cancer Symposium®
OverviewThis annual meeting will provide an update on advances in the current management of lung cancer, as well as a focus on the future.
Participants will have an opportunity to learn from engaging presentations delivered by leading experts. Sessions will include emerging data, discussions on evolving standards of care, tumor board style case reviews and information that has the potential to impact their practice in the short term.
Faculty will discuss key clinical topics, including:
- Optimal use of EGFR/ALK TKIs
- Best practices in the treatment of advanced stage lung cancers
- Patient management across multiple lines of therapy
- Tailored therapy for individual patient
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.
Program ChairsMark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Disclosure Policy and Resolution of Conflicts of Interest (COI)It is the policy of PER® to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with the ACCME Standards for Commercial SupportSM, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to start of each activity. Participants are notified prior to the activity of the presence or absence of relevant financial relationships between faculty and commercial interests. Information disclosed includes the name of the faculty, nature of the relevant financial relationship (e.g., member of speaker's bureau, grant/research support, or consulting arrangement), and the name of the company/organization with which the relationship exists. Additionally, prior to the start of each activity PER® discloses the source of commercial support to the participants.
The following individuals have no relevant financial relationships with commercial interests to disclose:
Faculty, Staff, and Planners’ Disclosures
Maria E. Arcila, MD; Abraham Chachoua, MD; Jamie E. Chaft, MD; Jorge E. Gomez, MD; Jeffrey G. Schneider, MD.
The staff of PER®, LLC: Debbie Augustus; Leigh Anne Bongiovanni; Tiffany Fattizzi; Ann C. Lichti, CCMEP; and David Lee, PhD.
The following individuals have relevant financial relationships with commercial interests to disclose:
Richard J. Gralla, MD -- Grant/Research Support: NIH/NCI; Consultant: Merck, Eisai; Balazs Halmos, MD -- Grant/Research Support: Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Dekkun, Daiichi-Sankyo, Eli Lilly, Bristol-Myers Squibb, Incyte, Merck, Roche, Novartis, Astex; Peter Hammerman, MD, PhD -- Consultant: Astra-Zeneca, Janssen, ImClone, Ariad; Stock/Shareholder: Pfizer; Christine L. Hann, MD, PhD -- Grant-Research Support: GlaxoSmithKline; Harry D. Harper, MD -- Speaker's Bureau: Eli Lilly, Boehringer-Ingelheim; Roy S. Herbst, MD, PhD -- Consultant: SAB, Kolltan, N-of-One, Inc., DiaTech Oncology, Quintiles Inc., Biothera; Mark G. Kris, MD -- Grant/Research Support: Puma Biotechnology, Pfizer; Consultant: AstraZeneca, Threshold, Array; Benjamin P. Levy, MD -- Consultant: Genentech, Eli Lilly, Pfizer, Biodesix, Boehringer Ingelheim, Celgene; Speaker's Bureau: Genentech , Eli Lilly; Thomas J. Lynch, Jr., MD -- Honoraria/Stock/Board of Directors: Bristol-Myers Squibb; Honoraria/Stock/Scientific Advisory Board: Arvinas; Stock/Stockholder: Infinity Pharmaceutials; Royalties/Patent Holder: Partners Healthcare EGFR mutation testing patent; Roman Perez-Soler, MD -- Consultant: Certex, Clovis, Teva, Boehringer-Ingelheim; Harry Raftopoulos, MD -- Grant/Research Support: Novartis, Roche, Pfizer; Consultant: Merck; Gregory Riely, MD, PhD -- Grant/Research Support: Novartis, Pfizer, Infinity, GSK, Millennium; Consultant: Novartis; Bryan J. Schneider, MD -- Grant/Research Support: Celgene, Lilly; Consultant: Genentech; Speaker's Bureau: Genentech; Steven E. Vogl, MD -- Consultant/Advisory Board: Janssen; Stock/Shareholder: Amgen, Bristol-Myers Squibb.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
Off-Label Disclosure and Disclaimer
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Physicians' Education Resource®, LLC, complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
Physician Payments Sunshine Act
The Symposium is jointly provided by the Icahn School of Medicine at Mount Sinai and The Chemotherapy Foundation a non-profit organization supporting cancer research.
The Symposium is a multi-specialty cancer conference bringing advances in treatment that meet the learning needs of practicing oncologists in academia and community medicine while providing unique applications of electronic enhancements to a medical education activity.
For more information, visit: http://www.chemotherapyfoundationsymposium.org
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.